Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS: We conducted 2 parallel phase I/II studies (ClinicalTrials.gov...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Ramos, Carlos A., Grover, Natalie S., Beaven, Anne W., Lulla, Premal D., Wu, Meng-Fen, Ivanova, Anastasia, Wang, Tao, Shea, Thomas C., Rooney, Cliona M., Dittus, Christopher, Park, Steven I., Gee, Adrian P., Eldridge, Paul W., McKay, Kathryn L., Mehta, Birju, Cheng, Catherine J., Buchanan, Faith B., Grilley, Bambi J., Morrison, Kaitlin, Brenner, Malcolm K., Serody, Jonathan S., Dotti, Gianpietro, Heslop, Helen E., Savoldo, Barbara
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655020/
https://ncbi.nlm.nih.gov/pubmed/32701411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01342
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares